First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.

Marcelo V. Negrão, Scott Kopetz, Amir A. Jazaeri et al.|Journal of Clinical Oncology|2022

Cited by 3